Significant Savings with a Stepped Care Model for Treatment of Patients with Intermittent Claudication  by Fokkenrood, H.J.P. et al.
Selected Abstracts from the October Issue of the
European Journal of Vascular and Endovascular Surgery
A. Ross Naylor, MBChB, MD, FRCS, Editor-in-Chief, and Philippe H. Kolh, MD, PhD, Senior EditorMid-term Outcomes and Aortic Remodelling After Thoracic
Endovascular Repair for Acute, Subacute, and Chronic Aortic
Dissection: The VIRTUE Registry
The VIRTUE Registry Investigators. Eur J Vasc Endovasc Surg
2014;48:361-9.
Objective: The VIRTUE Registry describes the mid-term clinical and
morphological results of thoracic endovascular repair (TEVR) in patients
with type B aortic dissection.
Methods: This was a prospective cohort study. The VIRTUE Regis-
try is a prospective, multicentre clinical trial that enrolled patients with
complicated acute (<15 days), subacute (15e92 days), and chronic (>92
days) type B aortic dissections treated with the Valiant endograft. One hun-
dred patients were enrolled and the clinical outcomes described at the 3-
year follow-up. Analysis of the aortic area and false lumen thrombosis rates
deﬁned the morphological response to TEVR in the three clinical groups.
Results: Three-year all-cause mortality (18%, 4%, and 24%), dissection
related mortality (12%, 4%, and 9%), aortic rupture (2%, 0%, and 4%), retro-
grade type A dissection (5%, 0%, and 0%), and aortic reintervention rates
(20%, 22%, and 39%) were, respectively, deﬁned for patients with acute
(n = 50), subacute (n = 24), and chronic (n = 26) dissections. Analysis of
aortic morphology observed that patients with subacute dissection demon-
strated a similar degree of aortic remodelling to patients with acute dissec-
tion. Patients with acute and subacute dissection exhibited greater aortic
plasticity than patients with chronic dissection.
Conclusions: The principle clinical ﬁndings suggest that TEVR is able
to provide good protection from aortic-related death in the mid-term,
but with a high rate of aortic reintervention. Analysis of aortic morphology
suggested that aortic remodelling in subacute patients is similar to the acute
group. Retention of aortic plasticity in the subacute group lengthens
the therapeutic window for the treatment of uncomplicated type B
dissection.
Inﬂuence of Cardiovascular Risk Factors on Levels of Matrix
Metalloproteinases 2 and 9 in Human Abdominal Aortic Aneurysms
Dilmé J.-F., Bellmunt S., Camacho M., Solà-Villà D., Romero J.-M.,
Escudero J.-R., Vila L. Eur J Vasc Endovasc Surg 2014;48:372-9.
Objective: To evaluate the inﬂuence of cardiovascular risk factors on
levels of matrix metalloproteinases (MMP) 2 and 9 in human abdominal
aortic aneurysms (AAA).
Methods: Aortic samples were collected from patients who under-
went AAA repair (n = 89). Patients were stratiﬁed according to the
maximum transverse aorta diameter: small diameter (<55 mm), moderate
diameter (55e69.9 mm) and large diameter ($70 mm). Aortic walls
were studied using real-time PCR and immunohistochemistry. MMP-2,
MMP-9, a-actin, CD45, and CD68 transcript levels were determined rela-
tive to b-actin. Quantitative data were expressed as median (IQ-range).
Results: No differences were found in MMP-2 expression between
the patient groups, which was mainly associated with vascular smooth
muscle cells (VSMC); however, MMP-9 displayed the maximum level in
the moderate-diameter group, associated with inﬁltrating macrophages.
Current smoking (CS) and renal insufﬁciency (RI) signiﬁcantly increased
local levels of MMP-2 (CS 349.5 [219.5e414.1] vs. no-CS 184.4
[100.0e320.5]; p < .008; RI 286.8 [189.6e410.8] vs. no-RI 177.3
[99.3e326.9]; p = .047). Nevertheless, after stepwise linear regression anal-
ysis only CS remained as an independent variable predicting local levels of
MMP-2 (p = .002). No risk factors inﬂuenced local levels of MMP-9.
Conclusions: The results show that local levels of MMP-2, an impor-
tant factor for AAA development, were increased in current smoking AAA
patients. MMP-2 was mainly associated with VSMC. It is suggested that
MMP-2 could contribute signiﬁcantly to the increased AAA growth rate
observed in current smoking patients. These ﬁndings support inclusion of
smokers in screening for aneurysmal disease, and emphasize the need for
more aggressive monitoring of aneurysmal disease outside the surgical rangein patients who smoke at the time of diagnosis and in those who continue to
smoke during follow-up.
Type II Endoleak: Conservative Management Is a Safe Strategy
Sidloff D.A., Gokani V., Stather P.W., Choke E., Bown M.J., Sayers R.D.
Eur J Vasc Endovasc Surg 2014;48:389-97.
Objective: Type II endoleak is the most common complication after
endovascular abdominal aortic aneurysm repair (EVAR); however, its natu-
ral history is unclear. The aim of this study was to examine the incidence and
outcomes of type II endoleak, at a single institution after EVAR.
Methods: A total of 904 consecutive patients who underwent EVAR
between September 1995 and July 2013 at a single centre were entered
onto a prospective database. All patients were followed up by duplex ultra-
sound (DUSS). Patients who developed type II endoleak were compared for
preoperative demographics, mortality, and sac expansion.
Results: A total of 175(19%) patients developed type II endoleak
over a median follow-up of 3.6 years (1.5e5.9 years); 54% of type II
endoleaks spontaneously resolved within 6 months (0.25e1.2 years).
No difference was found in preoperative demographics or choice of
endograft between the two groups. Survival was signiﬁcantly higher in
the group with type II endoleak (94.1% vs 85.6%; p = .01) and this effect
was most pronounced in those with late type II endoleaks (97.7% vs.
85.6% p = .004). No difference was seen in aneurysm-related mortality
or rate of type I endoleak between the two groups. Freedom from sac
expansion (>5 mm from preoperative diameter) was signiﬁcantly lower
in the group of patients with type II endoleak (82.5% vs. 93.2%, p =
.0001); however, at a threshold of >10 mm from preoperative diameter
no difference was seen.
Conclusions: Patients with isolated type II endoleak demonstrate
equivalent aneurysm-related mortality and an improved survival.
Signiﬁcant Savings with a Stepped Care Model for Treatment of
Patients with Intermittent Claudication
Fokkenrood H.J.P., Scheltinga M.R.M., Koelemay M.J.W., Breek J.C.,
Hasaart F., Vahl A.C., Teijink J.A.W. Eur J Vasc Endovasc Surg
2014;48:421-7.
Objectives: International guidelines recommend supervised exercise
therapy (SET) as primary treatment for intermittent claudication (IC).
The aim of this study was to calculate treatment costs in patients with IC
and to estimate nationwide annual savings if a stepped care model (SCM,
primary SET treatment followed by revascularization in case of SET failure)
was followed.
Methods: Invoice data of all patients with IC in 2009 were obtained
from a Dutch health insurance company (3.4 million members). Patients
were divided into three groups based on initial treatment after diagnosis
(t0). The SET group received SET initiated at any time between 12 months
before and up to 3 months after t0. The intervention group (INT) under-
went endovascular or open revascularization between t0 and t+3 months.
The third group (REST) received neither SET nor any intervention. All pe-
ripheral arterial disease related invoices were recorded during 2 years and
average costs per patient were calculated. Savings following use of a SCM
were calculated for three scenarios.
Results: Data on 4954 patients were analyzed. Initial treatment
was SET (n = 701, 14.1%), INT (n = 1363, 27.5%), or REST (n =
2890, 58.3%). Within 2 years from t0, invasive revascularization in the
SET group was performed in 45 patients (6.4%). Additional interven-
tions (primary at other location and/or re-interventions) were per-
formed in 480 INT patients (35.2%). Some 431 REST patients
received additional SET (n = 299, 10.3%) or an intervention (n = 132,
4.5%). Mean total IC related costs per patient were V2,191, V9851
and V824 for SET, INT, and REST, respectively. Based on a hypothet-
ical worst, moderate, and best case scenario, some 3.8, 20.6, or 33.01097
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mented in the Dutch healthcare system.
Conclusion: Implementation of a SCM treatment for patients with
IC may lead to signiﬁcant savings of health care resources.
Biochemical and Immunomorphological Evaluation of Hepatocyte
Growth Factor and c-Met Pathway in Patients with Critical Limb
Ischemia
Vasuri F., Fittipaldi S., Abualhin M., Degiovanni A., Gargiulo M., Stella A.,
Pasquinelli G. Eur J Vasc Endovasc Surg 2014;48:428-35.
Objectives: Hepatocyte growth factor (HGF), the c-Met receptor,
and hypoxia-inducible factor (HIF) are crucial for regenerative processes
including ischemic wound healing. The aims of the present study are (a)
to analyze the tissue c-Met and HIF-1a expression in skin from patients
with critical limb ischemia (CLI); (b) to compare the serum HGF levels
of CLI and control subjects.
Methods: This is a prospective, controlled, single-center study. Thir-
ty-seven patients were enrolled. A skin sample adjacent to the ischemic
lesion was taken from 20 patients with CLI; skin samples were taken from
the surgical wounds of 17 patients surgically treated for abdominal aortic
aneurysm as healthy controls. Serum samples were taken in all cases. Sam-
ples were formalin ﬁxed, parafﬁn embedded, and routinely processed. Tissue
inﬂammation was histologically assessed. Immunohistochemistry was per-
formed with antibodies against total c-Met receptor, activated Met (p-
Met), and HIF-1a. RT-polymerase chain reaction was used to quantify
HIF-1a mRNA. The enzyme-linked immunosorbent assay was performed
to evaluate serum HGF levels.
Results: With immunohistochemistry, while total c-Met was un-
changed, different patterns of p-Met positivity were observed between CLI
and control cases (p< .001). In particular, CLI skin showed a total negativity
or membrane positivity for p-Met (19/20 cases), while control skin mainly
showed cytoplasmic positivity in the epidermal basal layer (16/17 cases).
HIF-1a was diffusely lost in CLI, but HIF-1a mRNA was threefold higher
than in controls. Finally, mean serum HGF levels were 590.5 pg/mL and
2380.0 pg/mL in CLI and control groups respectively (p < .001).Conclusions: In CLI patients a signiﬁcant decrease in serum HGF
levels, concomitant with a loss of skin HIF-1a stabilization and a lack of
c-Met phosphorylation were seen, probably driving a decrease in wound-
healing functions. The next hypothesis is that HGF application might reac-
tivate the c-Met receptor, stabilizing the normal wound healing process.
Therapeutic Effect of Compression Stockings Versus no Compression
on Isolated Superﬁcial Vein Thrombosis of the Legs: A Randomized
Clinical Trial
Boehler K., Kittler H., Stolkovich S., Tzaneva S. Eur J Vasc Endovasc Surg
2014;48:463-9.
Objective/Background: Leg compression is considered basic treat-
ment for superﬁcial vein thrombosis (SVT), although scientiﬁc proof for
its efﬁcacy is lacking. The aim of the study was to evaluate the therapeutic
effect of compression stockings on isolated SVT of the legs.
Methods: This was a single-center randomized controlled trial.
Eighty patients with isolated SVT of the legs were instructed to wear
compression stockings (23e32 mmHg) (CG) or no compression (NCG)
for 3 weeks. All patients received low molecular weight heparin (LMWH)
at prophylactic dosage. Non-steroidal anti-inﬂammatory drugs (NSAIDs)
were allowed. The primary outcome variable was the reduction of pain as
assessed by a visual analog scale (VAS) and the Lowenberg test. Secondary
outcomes were the consumption of analgesics, thrombus length, skin ery-
thema, D-dimer, and quality of life (QoL).
Results: Seventy-three patients completed the study. Clinical symp-
toms and QoL signiﬁcantly improved from baseline to day 21 in both
groups (p < .001 for VAS, Lowenberg test, thrombus length, and erythema;
p < .006 for QoL), and consumption of analgesics and D-dimer signiﬁcantly
decreased (p < .001). There was no signiﬁcant difference between the
groups for all tested variables. At day 7, patients in the CG revealed a signif-
icantly faster thrombus regression (p = .02).
Conclusion: Adding compression stockings for 3 weeks to LMWH
and NSAIDs does not bring signiﬁcant additional beneﬁt in the treatment
of isolated SVT. When worn for 1 week, compression stockings stimulate
signiﬁcantly faster thrombus regression.
